Editor's Corner

Today I'm reporting live from BIO, the annual conference of the Biotechnology Industry Organization. The show is now fully underway this morning as 18,000 biotech players from around the globe arrive in Philadelphia. This is a chance for hundreds of biotech companies to tout their progress and discuss stem cell research, the growing alliance between biotech companies and big pharma, and what India and China mean for the future of drug development. FierceBiotech will put the spotlight on emerging private biotech companies in this evening's announcement of the Fierce 15, with the special issue coming out tomorrow for all readers. - John Carroll

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.